Business
CTT Pharmaceutical Holdings, Inc. Files Form S-1 Registration Statement and Advances Equity Line of Credit and Scientific Development Milestones
CTT Pharmaceutical Holdings, Inc. Files Form S-1 Registration Statement and Advances Equity Line of Credit and Scientific Development Milestones.
About this update from Ctt Pharmaceutical Holdings, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n CTT Pharmaceutical Holdings, Inc. Files Form S-1 Registration Statement and Advances Equity Line of Credit and Scientific Development Milestones\r\n \r\n \r\n\r\n\r\nCTT Pharmaceutical Holdings, Inc. Files Form S-1 Registration Statement and Advances Equity Line of Credit and Scientific Development Milestones\r\n\r\n\r\n\r\n\r\n\r\nTAMPA, FL / ACCESS Newswire / December 30, 2025 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) today announces the filing of a Form S-1 registration statement with the United States Securities and Exchange Commission. The filing marks an important milestone in the Company's transition to fully reporting status and reflects management's commitment to regulatory transparency, operational discipline, and long-term corporate development. The Company also continues to advance its initial $3,000,000 Equity Line of Credit, which provides strategic financial flexibility to support commercialization initiatives and ongoing scientific progress. Additionally, CTT and RH2 Equity Partners have agreed and signed an agreement to increase the equity line to $10,000,000. The increase will be used to help CTT scale its future product lines.\r\n The Company recently received approval for publication of a peer-reviewed manuscript that highlights general advances in micelle-enhanced thin film oral delivery systems. The paper examines this innovative technology across a broad scientific landscape that helps build greater awareness of the technology and the science that supports our approach. CTT's scientific team is now preparing a perspective article as the next step in the peer review pipeline, followed by a comprehensive research paper planned for 2026. These milestones strengthen the Company's scientific foundation and support future regulatory and commercial pathways for its platform.\r\n CTT is also progressing toward manufacturing readiness and regulatory alignment as it prepares for commercial deployment of its technology. Management believes that the combination of scientific validation, capital access, and corporate compliance initiatives places the Company on a constructive path toward sustainable execution.\r\n \"This is a significant milestone for CTT Pharma,\" said Ryan Khouri, Chief Executive Officer of CTT Pharmaceutical Holdings, Inc. \"The filing of our Form S-1 is a strong step forwa...